Hypersensitivity Pneumonitis Diagnosis and Treatment
Diagnosis
- The diagnosis of hypersensitivity pneumonitis (HP) should be confirmed based on CT imaging patterns, including typical nonfibrotic HP and typical fibrotic HP, which show profuse poorly defined centrilobular nodules of ground-glass opacity, inspiratory mosaic attenuation with three-density sign, or inspiratory mosaic attenuation with air-trapping, as well as exposure history and multidisciplinary discussion (MDD) for uncertain cases, according to the American Thoracic Society 1
- Identification of a clinically relevant inhalational antigen (IA) exposure is crucial for the diagnosis of HP, as stated by the American College of Chest Physicians 2
- Clinical improvement after antigen avoidance supports the diagnosis of HP, though absence of improvement doesn't rule it out, as noted by the American College of Chest Physicians 1
- Relying solely on clinical improvement with medical therapy should not be used alone to confirm an HP diagnosis, as stated by the American Thoracic Society and the American College of Chest Physicians 1, 2
Treatment
- Complete elimination of the offending antigen is the cornerstone of treatment for HP, and clinical improvement after antigen avoidance supports the diagnosis, as noted by the American College of Chest Physicians 1
- For symptomatic patients with non-fibrotic HP, consider corticosteroids, such as prednisone 0.5-1 mg/kg/day (maximum 60 mg/day) with gradual taper over 4-6 weeks, as recommended by the American Thoracic Society 1
- For patients with fibrotic HP, longer treatment courses with consideration of steroid-sparing agents may be necessary, as suggested by the American College of Chest Physicians 1
- The following table summarizes the recommended corticosteroid dosing for HP:
| Condition | Recommended Dose |
|---|---|
| Non-fibrotic HP | Prednisone 0.5-1 mg/kg/day (maximum 60 mg/day) |
| Fibrotic HP | Longer treatment courses with consideration of steroid-sparing agents |
| Severe disease or respiratory failure | Methylprednisolone 1-2 mg/kg/day IV |
| Grade 2 pneumonitis | Prednisone 1mg/kg/day (maximum 60 mg/day) |
| Grade 3-4 pneumonitis | Methylprednisolone 2-4 mg/kg/day IV |
- Response assessment for HP involves improvement in pulmonary function tests (FVC and DLCO), resolution of radiologic abnormalities, and symptom improvement (especially cough and dyspnea) 8, 3, 4
Management of Complications
- Pneumocystis pneumonia prophylaxis should be considered for patients receiving ≥20 mg of methylprednisolone or equivalent for ≥4 weeks, as recommended by the American College of Chest Physicians 1
- Calcium and vitamin D supplementation should be considered for prolonged corticosteroid use, and proton pump inhibitors for gastric protection in patients with grade 2-4 pneumonitis, as suggested by the American Thoracic Society 1
- For patients requiring prolonged therapy or experiencing significant steroid-related adverse events, consider steroid-sparing agents such as mycophenolate mofetil or azathioprine, which may help stabilize lung function in fibrotic HP, as stated by the American College of Chest Physicians 2
- Antifibrotic medications may be considered as second-line therapy for progressive fibrotic HP despite immunosuppression 2
Pitfalls to Avoid
- Delayed diagnosis can occur if HP is not considered in the differential diagnosis, and a thorough occupational/environmental history is not obtained, as noted by the American College of Chest Physicians 1
- Inadequate antigen avoidance can lead to continued disease progression, and abrupt corticosteroid discontinuation can cause recurrence, as stated by the American Thoracic Society 1
- Treating asymptomatic patients with normal spirometry with corticosteroids is not recommended, as suggested by the American College of Chest Physicians 1
- Fatal progression can occur despite appropriate treatment, particularly in fibrotic HP, highlighting the importance of early diagnosis and aggressive management 2